国际T细胞项目网络提出的局限期外周T细胞淋巴瘤SALENTO预后模型
研究基于国际T细胞项目(TCP)2006—2018年登记的211例局限期外周T细胞淋巴瘤(PTCL)患者,分析总生存(OS)与无进展生存(PFS)并建立SALENTO预后模型,在澳大利亚和巴西登记处103例患者中验证;模型按年龄>60岁、乳酸脱氢酶升高、血清白蛋白降低分为低、中、高危三组,5年OS分别为78%、46%、25%(P<0.001)。
要点
- SALENTO模型基于年龄>60岁、LDH升高、血清白蛋白降低3个独立预后因素构建。
- 低危(评分0)、中危(评分1)、高危(评分2-3)5年OS分别为78%、46%、25%(P<0.001)。
- 验证队列103例中3组分布与结局与建模队列类似,区分能力优于现有预后指数。
核心结论
- SALENTO模型是客观、简单且稳健的预后工具,高危组结局差,与晚期疾病相当,应考虑创新一线方案。
研究设计与样本
- 基于国际T细胞项目(TCP,#NCT01142674)2006—2018年登记的211例局限期常见结内PTCL(PTCL-NOS、AITL、ALCL)患者建立预后模型,并在澳大利亚和巴西登记处103例独立数据集中验证。
主要发现
- 中位年龄59岁(范围18-88),中位随访49个月;127例(78%)接受蒽环类方案,5例(3%)仅放疗,24例(15%)化疗+放疗。
- 5年OS和PFS分别为47%和37%。
- 年龄>60岁、LDH升高和血清白蛋白降低为独立预后因素。
- 低危(26%,评分0)、中危(41%,评分1)、高危(33%,评分2-3)5年OS分别为78%(95%CI 29-127)、46%(95%CI 24-68)、25%(95%CI 20-30),P<0.001。
- 低危、中危、高危5年PFS分别为66%(95%CI 33-99)、37%(95%CI 9-65)、17%(95%CI 9-25),P<0.001。
关键数值与推荐
- SALENTO模型评分:年龄>60岁、LDH升高、血清白蛋白降低各计1分,总分0-3分。
- 低危:评分0,5年OS 78%(95%CI 29-127),5年PFS 66%(95%CI 33-99)。
- 中危:评分1,5年OS 46%(95%CI 24-68),5年PFS 37%(95%CI 9-65)。
- 高危:评分2-3,5年OS 25%(95%CI 20-30),5年PFS 17%(95%CI 9-25)。
临床怎么用
- 作者认为高危组结局差,与晚期疾病相当,应考虑创新一线方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP) (#NCT01142674) to develop a model to predict overall survival (OS) for the common nodal PTCL subtypes (PTCL-NOS, AITL, ALCL). The model was validated in an independent data set from Australian and Brazilian registries. 211 patients registered in the TCP between 2006-2018 were studied. The median age was 59 years (range 18-88) and median follow-up was 49 months. One hundred twenty-seven patients (78%) received anthracycline-based regimens, 5 patients (3%) radiotherapy alone (RT), 24 patients (15%) chemotherapy+RT. 5-year OS and PFS were 47% and 37%, respectively. Age >60 years, elevated LDH and low serum albumin were independent prognostic factors. The model identified 3 groups with low- (26%, score 0), intermediate- (41%, score 1), and high-risk (33%, score 2-3) with 5-year OS of 78% (95% confidence interval [95% CI], 29-127), 46% (95% CI, 24-68), and 25% (95% CI, 20-30), respectively (P < 0.001) and 5-year PFS of 66% (95% CI, 33-99), 37% (95% CI, 9-65), and 17% (95% CI, 9-25), respectively (P < 0.001). The model demonstrated greater discriminatory power than established prognostic indices and an analogous distribution and outcomes in the 3 groups in the validation cohort of 103 patients. The SALENTO Model (Limited Stage Peripheral T-Cell Lymphoma Prognostic Model) is an objective, simple and robust prognostic tool. The high-risk group has poor outcomes, comparable to advanced stage disease, and should be considered for innovative first-line approaches.
引用
- Hapgood G, Civallero M, Stepanishyna Y, et al. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Adv. 2023. PMID: 37163360. doi:10.1182/bloodadvances.2023010037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。